Back to Search Start Over

Evaluation of plasma IL-21 as a potential biomarker for type 1 diabetes progression.

Authors :
Schroderus AM
Poorbaugh J
McElyea S
Beasley S
Zhang L
Näntö-Salonen K
Rintamäki R
Pihlajamäki J
Knip M
Veijola R
Toppari J
Ilonen J
Benschop RJ
Kinnunen T
Source :
Frontiers in immunology [Front Immunol] 2023 Jun 21; Vol. 14, pp. 1157265. Date of Electronic Publication: 2023 Jun 21 (Print Publication: 2023).
Publication Year :
2023

Abstract

IL-21 is a multifunctional cytokine linked with the pathophysiology of several autoimmune diseases, including type 1 diabetes. In this study, our aim was to examine plasma IL-21 levels in individuals at different stages of type 1 diabetes progression. We measured plasma IL-21 levels, as well as levels of other key pro-inflammatory cytokines (IL-17A, TNF-α and IL-6), from 37 adults with established type 1 diabetes and 46 healthy age-matched adult controls, as well as from 53 children with newly diagnosed type 1 diabetes, 48 at-risk children positive for type 1 diabetes-associated autoantibodies and 123 healthy age-matched pediatric controls using the ultrasensitive Quanterix SiMoA technology. Adults with established type 1 diabetes had higher plasma IL-21 levels compared to healthy controls. However, the plasma IL-21 levels showed no statistically significant correlation with clinical variables, such as BMI, C-peptide, HbA1c, or hsCRP levels, evaluated in parallel. In children, plasma IL-21 levels were almost ten times higher than in adults. However, no significant differences in plasma IL-21 levels were detected between healthy children, autoantibody-positive at-risk children, and children with newly diagnosed type 1 diabetes. In conclusion, plasma IL-21 levels in adults with established type 1 diabetes were increased, which may be associated with autoimmunity. The physiologically high plasma IL-21 levels in children may, however, reduce the potential of IL-21 as a biomarker for autoimmunity in pediatric subjects.<br />Competing Interests: JPo, SM, SB, LZ, and RB are employees of Eli Lilly & Company and may own stock. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.<br /> (Copyright © 2023 Schroderus, Poorbaugh, McElyea, Beasley, Zhang, Näntö-Salonen, Rintamäki, Pihlajamäki, Knip, Veijola, Toppari, Ilonen, Benschop and Kinnunen.)

Details

Language :
English
ISSN :
1664-3224
Volume :
14
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
37415982
Full Text :
https://doi.org/10.3389/fimmu.2023.1157265